Akuammine (Akuamma Indole Alkaloid · Opioid-Receptor Ligand · Informational)

Compound	Akuammine (Vincamajoridine)
Chemical class	Alkaloid — Indole (akuammiline-related monoterpenoid indole alkaloid)
CAS	3512-87-6
Primary source	Picralima nitida (akuamma) seeds — principal alkaloid, ~0.56% of dried seed
Key applications	Opioid-receptor ligand; antimalarial research; informational-only
Claim strength	Emerging
Typical form	Research reference; not offered as a supplement ingredient
Buy from Herbuno	Informational reference — see HerbIQ Compound Index →

Name origin: Akuammine, also called vincamajoridine, takes its name from akuamma, the indigenous West African name for Picralima nitida; the whole family of akuamma alkaloids is named the same way. It is a monoterpenoid indole alkaloid structurally related to both yohimbine and mitragynine, and it is the most abundant alkaloid in the seed, at roughly 0.56% of the dried powder. Traditional use: The seeds of the akuamma tree have a long history in West African, particularly Ghanaian, traditional medicine as a treatment for pain, fever, and malaria, and they have also been used for opioid withdrawal. Ground akuamma seed is sold in some markets as a herbal analgesic, and this ethnobotanical reputation for pain relief is what drew pharmacological attention to the seed alkaloids. Research trajectory: A 1993 investigation identified akuammine as an antimalarial indolemonoterpene alkaloid of the seeds Kapadia 1993. Its opioid pharmacology has been studied repeatedly and with somewhat divergent results: modern isolation work using pH-zone-refining countercurrent chromatography produced six akuamma alkaloids in high purity and screened five of them against a panel of more than 40 CNS receptors, identifying the opioid receptors as their primary targets and finding akuammine among three alkaloids with micromolar activity at the mu-opioid receptor Creed 2021; subsequent semisynthetic work generated derivatives with substantially improved mu-opioid potency, demonstrating the scaffold's tractability Uprety 2023. Safety context: Because the akuamma alkaloids act at opioid receptors, they carry the dependence and safety considerations of that class; akuammine is documented here as a factual research reference and is not offered as an ingredient.

---

Evidence for Akuammine Applications

Opioid-receptor activity: In a receptor-panel screen of the purified akuamma alkaloids against more than 40 CNS targets, the opioid receptors were identified as their primary site of action, and akuammine was among three alkaloids showing micromolar activity at the mu-opioid receptor Creed 2021. Its affinity is low — earlier binding work placed it in the sub-micromolar to micromolar range, hundreds of times weaker than a selective mu agonist — and older isolated-tissue studies characterised it as a mu antagonist, so the literature is not fully concordant. Claim strength: Emerging.

Scaffold for opioid medicinal chemistry: Because akuammine is structurally distinct from morphine- and fentanyl-type ligands, it has attracted interest as a novel opioid scaffold; a collection of semisynthetic derivatives produced compounds with markedly improved mu-opioid potency and selectivity, and the most potent showed increased efficacy in tail-flick and hot-plate antinociception assays Uprety 2023. Claim strength: Emerging.

Antimalarial activity: Akuammine was identified as an antimalarial indolemonoterpene alkaloid of Picralima nitida seeds Kapadia 1993, consistent with the traditional use of akuamma seed against fever and malaria; laboratory antiplasmodial activity has been demonstrated, though it does not approach the potency of standard antimalarial drugs. Claim strength: Emerging.

Weak intrinsic antinociception: Despite the seed's traditional analgesic reputation, purified akuammine produces only minimal effects in animal models of antinociception, and this gap between the crude seed's reputation and the isolated alkaloid's weak activity is a recurring theme in the akuamma literature Uprety 2023. Claim strength: Emerging.

Abundance and seed composition: Akuammine dominates the akuamma seed alkaloid profile at around 0.56% of dried powder, with akuammidine and pseudo-akuammigine present at far lower levels, so any whole-seed preparation delivers akuammine as its principal alkaloid by a wide margin Creed 2021. Claim strength: Emerging.

---

Dosage & Formulator Specification

Akuammine is documented here for research and formulator education only; Herbuno does not offer it as an ingredient, and no established human dose exists for the purified alkaloid. Its activity at opioid receptors places it outside the botanical ingredient range regardless of the fact that akuamma seed is sold in some markets.

Where akuamma seed material is encountered, the analytical reality is that akuammine is the dominant alkaloid at roughly 0.56% of dried seed, with the other akuamma alkaloids present at an order of magnitude less. Any characterisation of the material therefore turns on total alkaloid content and on the akuammine fraction specifically, determined chromatographically; assumed composition is not a defensible basis given the natural variability of seed batches.

The pharmacological picture warrants care rather than enthusiasm. The traditional analgesic reputation of the seed sits awkwardly against the finding that purified akuammine has weak opioid affinity and minimal antinociceptive effect in animal models, and the older and newer literature disagree on whether it behaves as a mu agonist or antagonist. That combination — genuine opioid-receptor engagement, weak and disputed intrinsic activity, and an established folk reputation — is exactly the profile that calls for factual documentation without any implied endorsement or supply pathway.

This monograph provides chemical, pharmacological, and safety context within the HerbIQ index, situating akuammine alongside the other akuamma alkaloids and the opioid-active indole alkaloids covered elsewhere, and does not constitute sourcing guidance.

---

Frequently Asked Questions — Akuammine

What is akuammine?
Akuammine (vincamajoridine) is the most abundant alkaloid in the seeds of the akuamma tree, Picralima nitida, comprising roughly 0.56% of the dried seed powder. It is a monoterpenoid indole alkaloid structurally related to yohimbine and mitragynine, and it interacts with opioid receptors.

What does akuammine do at opioid receptors?
Reported findings differ by preparation and assay. Akuammine binds with highest affinity to mu-opioid sites but has been characterised in isolated-tissue work as an antagonist there, while more recent receptor-panel studies describe it as having micromolar agonist activity at the mu-opioid receptor. Either way its affinity is low, several hundred-fold weaker than a selective mu agonist.

Why is akuammine informational-only?
Akuamma alkaloids act at opioid receptors, and compounds with opioid activity carry dependence and safety considerations that place them outside Herbuno's botanical ingredient range. This page documents akuammine factually for research and formulator education rather than offering it as an ingredient.

Is akuammine an antimalarial?
A 1993 study identified akuammine as an antimalarial indolemonoterpene alkaloid of Picralima nitida seeds, and akuamma seed has a traditional West African use against fever and malaria. The antiplasmodial activity has been demonstrated in laboratory models but is not comparable to standard antimalarial drugs.

Related compounds: Akuammidine, Akuammicine, Akuammiline, Mitragynine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery